has approved the expansion of the indications of the anti-cancer drug olaparib. Olaparib can now be used to treat patients with certain breast cancers that have spread and where the tumors are ...

AZ and Merck said that the approval makes Lynparza (olaparib) the only PARP inhibitor ... and neoadjuvant use has been added to the drug's label. "Most breast cancers are identified in the early ...

This week has seen two readouts for rivals from Clovis Oncology and Pfizer in prostate cancer – one of several indications on the Lynparza (olaparib ... the final label with the FDA.